Artelo Biosciences Q1 2025: Minimal Revenue, Balanced Assets/Liabilities

Ticker: ARTL · Form: 10-Q · Filed: May 13, 2025 · CIK: 1621221

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

ARTL Q1 2025: $0.001M revenue, assets = liabilities at $3.28M. Still early days.

AI Summary

Artelo Biosciences, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported minimal revenue, with $0.001 million in net sales. Total assets were $3.28 million, and liabilities were also $3.28 million. The company has a history of name changes, previously being known as Reactive Medical Inc. and Knight Knox Development Corp.

Why It Matters

This filing provides a snapshot of Artelo Biosciences' financial health at the start of 2025, indicating a company with very limited revenue generation and a balance between its assets and liabilities.

Risk Assessment

Risk Level: high — The company reports extremely low revenue, suggesting significant financial risk and dependence on future funding or product development success.

Key Numbers

Key Players & Entities

FAQ

What was Artelo Biosciences' net sales for the first quarter of 2025?

Artelo Biosciences reported net sales of $0.001 million for the first quarter of 2025.

What were the total assets and liabilities of Artelo Biosciences as of March 31, 2025?

As of March 31, 2025, Artelo Biosciences had total assets of $3.28 million and total liabilities of $3.28 million.

When did Artelo Biosciences file its Q1 2025 10-Q report?

Artelo Biosciences filed its Q1 2025 10-Q report on May 13, 2025.

What were Artelo Biosciences' previous company names?

Artelo Biosciences was formerly known as Reactive Medical Inc. and Knight Knox Development Corp.

What is the Standard Industrial Classification for Artelo Biosciences?

The Standard Industrial Classification for Artelo Biosciences is Pharmaceutical Preparations [2834].

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding ARTELO BIOSCIENCES, INC. (ARTL).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing